Drugs / SAMROTAMAB VEDOTIN
SAMROTAMAB VEDOTIN
also known as
ABBV-085 · Adc abbv-085 · Antibody-drug conjugate abbv-085 · PR-1498487 PAB-MMAE · Samrotamab vedotina · Samrotamab vedotine
targets LRRC15
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02565758 | Sep 2015 → Mar 2019 | breast carcinoma, head and neck squamous cell carcinoma, undifferentiated pleomorphic sarcoma | AbbVie | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAMROTAMAB VEDOTIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594513 ↗ |
| Known as | ABBV-085 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02565758 ↗ |
| Known as | Adc abbv-085 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594513 ↗ |
| Known as | Antibody-drug conjugate abbv-085 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594513 ↗ |
| Known as | PR-1498487 PAB-MMAE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594513 ↗ |
| Known as | Samrotamab vedotina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594513 ↗ |
| Known as | Samrotamab vedotine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594513 ↗ |
| Route | Intravenous | “Administered as an intravenous infusion in 28-day dosing cycles.” NCT02565758 ↗ |
| Target | LRRC15 | “the ABBV-085 ADC for patients with LRRC15+ tumors” PMID 35260879 ↗ May 2022 |